GlycoMimetics gets back on the IPO train with another pitch

GlycoMimetics is reviving its efforts to go public, filing another S-1 after pulling the plug on plans to cash out for as much as $86 million.

The Gaithersburg, MD, biotech's latest pitch is stripped of any and all dollar figures, saying only that the company will spend the lion's share of its haul on GMI-1271, an early-stage treatment for acute myeloid leukemia, and put the rest toward preclinical R&D and corporate expenses. GlycoMimitecs' lead candidate is the Phase III-ready GMI-1070, treating the rare vaso-occlusive crisis, and the biotech has handed over that drug's worldwide rights to partner Pfizer ($PFE) in exchange for up to $340 million in milestones.

GlycoMimetics' initial filing sought up to $86 million, eventually scaled down to around $64 million before getting the ax in November. The company never disclosed its thinking behind the withdrawal, but the standard "market conditions" complaint is a fair assumption.

So what's changed since November? If anything, 2013's historically bullish biotech market has only further slowed down since GlycoMimetics' first attempt, as high-dollar tank jobs from the likes of Amarin ($AMRN), Ariad ($ARIA) and Sarepta ($SRPT) seem to have scared off public investors. The company, however, was sitting on about $7.7 million in cash as of Sept. 30, meaning it's going to have to raise some more funds somehow if it plans to get GMI-1271 into Phase I trials on its own.

And while this has been the best year for biotech IPOs since 2000, things are settling down for the winter. The most recent entrants, TetraLogic ($TLOG) and Kindred Biosciences ($KIN), faced scaled-back share prices and delays on their way to Wall Street.

- here's the filing

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.